跳至主要内容
临床试验/NCT01464346
NCT01464346已完成不适用

A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use

Medtronic Diabetes14 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2011年11月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
90
试验地点
14
主要终点
Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites

研究概览

简要总结

The purpose of this study is to demonstrate the performance of the Enlite Sensor over an entire calibration and wear period of 146 hours (6 days) when inserted in the abdomen and buttock and used with the Revel 2.0 Pumps in subjects age 18 - 75 years.

详细描述

The study is a multi-center, prospective single-sample correlational design without controls. Between 4 and 10 investigational sites will be used during this study. All subjects will be assigned to treatment. Each subject will wear the following devices:

  1. Enlite Sensors (2) connected to MiniLinks (2)
  2. Revel 2.0 Pumps (2)

During the study each subject will be wearing 2 sensors and 2 pumps simultaneously. The pumps will be differentiated by color, and will have different calibration requirements during the in-clinic portions of the study. During the Frequent Sampling Tests:

  • GREEN pump will be calibrated 3-4 times spread throughout the day
  • RED pump will have the minimum calibration requirements (every 12 hours after the second calibration)

During home use (outside the clinic) BOTH pumps will be calibrated 3-4 times spread throughout the day.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is 18 - 75 years of age at time of screening
  • A clinical diagnosis of type 1 or 2 diabetes as determined by the
  • Investigator, for a minimum of 12 months duration:
  • Criteria for type 1 diabetes:
  • Required: Age of onset < 40 years of age
  • Required: History of insulin use only for management of diabetes
  • Required: history of normal weight or underweight at time of diagnosis.
  • Not required: Initial presentation of diabetic ketoacidosis.
  • Not required: History of diabetic ketoacidosis
  • Not required: Low fasting C-peptide
  • Criteria for type 2 diabetes:
  • Required: Age of onset ~ 40 years of age
  • Required: History of initial oral anti-diabetic use
  • Required: History of being overweight at time of diagnosis.
  • Type 2 insulin requiring is defined by type 2 diabetes subjects taking insulin with or without oral anti-diabetic agent and may also include: incretin mimetic, pramlintide or GLP agonist
  • Type 2 non-insulin requiring is defined by type 2 diabetes subjects who take oral medications and may also include: incretin mimetic, pramlintide or GLP agonist
  • Adequate venous access as assessed by investigator or appropriate staff

排除标准

  • Subject is unable to tolerate tape adhesive in the area of sensor placement.
  • Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)
  • Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks
  • Subject has a positive pregnancy screening test
  • Subject is female and plans to become pregnant during the course of the study
  • Subject has had a hypoglycemic seizure within the past 6 months
  • Subject has a history of a seizure disorder
  • Subject has central nervous system or cardiac disorder resulting in syncope
  • Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  • Subjects with hematocrit lower than 36%
  • SUbjects with a history of any cardiac arrhythmia, including atrial arrhythmias
  • Subjects with a history of adrenal insufficiency
  • Subjects with migraines

研究组 & 干预措施

Enlite sensor, Abdomen/Abdomen

Experimental

Subjects wearing 2 Enlite sensors in Abdomen

干预措施: Enlite Sensor (Device)

Enlite sensor, Abdomen/Buttock

Experimental

Subjects wearing 2 Enlite sensors in Abdomen/Buttock

干预措施: Enlite Sensor (Device)

Enlite sensor, Buttock/Buttock

Experimental

Subjects wearing 2 Enlite sensors in Buttock/Buttock

干预措施: Enlite Sensor (Device)

结局指标

主要结局

Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites

时间窗: Days 1, 3 and 6 of sensor wear

Primary endpoint is mean of daily percentage of sensor values within 30% of reference value (within 22.5 mg/dL if YSI \<75 mg/dL) with the minimum calibration (every 12 hour), combined abdomen and buttock insertion sites across all participants and all days.

次要结局

  • Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With 3-4 Calibrations Per Day, Combined Abdomen and Buttock Insertion(Days 1, 3 and 6 of sensor wear)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验